NLS Pharmaceutics Ltd.

Equities

NLSP

CH0523961370

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.1393 ^USD	-1.55%		+0.94%	-76.39%

Apr. 08	Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	CI
Apr. 03	NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	CI

NLS Pharmaceutics AG Achieves 90% Enrollment Milestone in Quilience® Phase 2a Clinical Trial for Patients with Narcolepsy

May 04, 2022 at 09:02 am EDT

NLS Pharmaceutics Ltd. announced that 90% of the 60 patients required to complete its Phase 2a clinical trial for Quilience (Mazindol ER) have been randomized and the Company continues to expect to report final results from this ground-breaking trial by mid-Q3 2022.

Latest news about NLS Pharmaceutics Ltd.

Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	Apr. 08	CI
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	Apr. 02	CI
NLS Pharmaceutics Ltd. announced that it expects to receive $1.75 million in funding	Mar. 19	CI
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance	Feb. 23	MT
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 06	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 01	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	Dec. 01	MT
Top Midday Gainers	Dec. 01	MT
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise	Dec. 01	MT
NLS Pharmaceutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value	Nov. 16	CI
Maxim Downgrades NLS Pharmaceutics to Hold From Buy	23-09-14	MT
Top Premarket Gainers	23-08-31	MT
NLS Pharmaceutics Ltd. cancelled the transaction announced on August 19, 2022	23-08-18	CI
Sector Update: Health Care Stocks Steady Pre-Bell Monday	23-07-03	MT
NLS Pharmaceutics' Mazindol ER Trial to Move to Phase 3	23-07-03	MT
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol	23-07-03	CI
NLS Pharmaceutics Ltd. Approves Board Appointments	23-06-30	CI
NLS Pharmaceutics Says Drug Interaction Studies of Mazindol Show 'Positive Results'	23-06-14	MT
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol	23-06-14	CI
NLS Pharmaceutics AG Announces Executive Changes	23-05-24	CI
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer	23-05-08	CI
NLS Pharmaceutics Ltd. Announces the Resignation of Chad Hellmann as Chief Financial Officer	23-05-05	CI
NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-05	CI
NLS Pharmaceutics Receives Green Light from the U.S. Food and Drug Administration to Proceed with Phase 3 Clinical Program for Quilience(R) for the Treatment of Narcolepsy	23-05-02	CI
NLS Pharmaceutics Ltd. Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2	23-03-27	CI

Chart NLS Pharmaceutics Ltd.

Duration

Period

More charts

Company Profile

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
NLS PHARMACEUTICS LTD.	-76.39%	6.57M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research

NLS Pharmaceutics Ltd.

Equities

NLSP

CH0523961370

Biotechnology & Medical Research

NLS Pharmaceutics AG Achieves 90% Enrollment Milestone in Quilience® Phase 2a Clinical Trial for Patients with Narcolepsy

Latest news about NLS Pharmaceutics Ltd.

Chart NLS Pharmaceutics Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research